Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer

Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Michael J., Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563098/
https://www.ncbi.nlm.nih.gov/pubmed/23383402
http://dx.doi.org/10.3389/fonc.2013.00009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563098/
https://www.ncbi.nlm.nih.gov/pubmed/23383402
http://dx.doi.org/10.3389/fonc.2013.00009

Ejemplares similares